Your browser is no longer supported. Please, upgrade your browser.
Settings
NMRD Nemaura Medical Inc. daily Stock Chart
NMRD [NASD]
Nemaura Medical Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own70.32% Shs Outstand20.25M Perf Week-13.99%
Market Cap93.01M Forward P/E- EPS next Y-2.00 Insider Trans- Shs Float6.66M Perf Month-37.49%
Income- PEG- EPS next Q-0.10 Inst Own0.01% Short Float0.12% Perf Quarter-46.59%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.23 Perf Half Y-49.83%
Book/sh0.01 P/B459.33 EPS next Y-566.70% ROA- Target Price3.25 Perf Year-72.98%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.83 - 19.90 Perf YTD-48.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.92% Beta-0.10
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low19.93% ATR0.75
Employees8 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)32.48 Volatility15.62% 14.86%
OptionableNo Debt/Eq0.00 EPS Q/Q3.40% Profit Margin- Rel Volume2.89 Prev Close5.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.61K Price4.59
Recom2.00 SMA20-24.15% SMA50-33.44% SMA200-47.11% Volume10,442 Change-10.56%
Dec-05-19 08:30AM  Nemaura Medical announces expansion of SugarBEAT® offering  with BEAT® Diabetes digital subscription services GlobeNewswire -17.81%
Dec-04-19 10:00AM  Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors GlobeNewswire
Nov-12-19 07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-11-19 09:00AM  Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019 GlobeNewswire
Oct-03-19 09:00AM  Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona GlobeNewswire +5.96%
Sep-20-19 11:31AM  Is Nemaura Medical (NASDAQ:NMRD) In A Good Position To Invest In Growth? Simply Wall St.
Sep-12-19 09:15AM  Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019 GlobeNewswire
Aug-09-19 01:30PM  Nemaura Medical Reports Quarterly Results for First Quarter Ended June 30, 2019 GlobeNewswire
Aug-07-19 08:30AM  Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch GlobeNewswire +9.03%
Aug-01-19 08:30AM  Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors GlobeNewswire +5.38%
Jul-18-19 09:00AM  Nemaura Medical Inc. Appoints Chris Avery as Vice President of Global Business Operations to Support Global Commercial Launch of SugarBEAT® GlobeNewswire
Jul-10-19 09:00AM  Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration GlobeNewswire +6.82%
Jun-17-19 09:00AM  Nemaura Provides Fiscal 2019 Year-End Business Update GlobeNewswire
Jun-14-19 09:00AM  Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report GlobeNewswire
May-29-19 09:00AM  Nemaura Announces CE Mark Approval of SugarBEAT® GlobeNewswire
May-27-19 07:36AM  The Nemaura Medical (NASDAQ:NMRD) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold Simply Wall St.
May-02-19 09:00AM  Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT® GlobeNewswire
Apr-23-19 08:00AM  Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT® GlobeNewswire
Apr-16-19 09:15AM  Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT® GlobeNewswire
Mar-28-19 08:30AM  Nemaura CEO Provides Update to Shareholders GlobeNewswire
Mar-12-19 09:18AM  Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region GlobeNewswire
Feb-12-19 09:15AM  Nemaura Reports Third Quarter 2018 Financial Results GlobeNewswire -7.94%
Feb-11-19 08:00AM  Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development GlobeNewswire +22.33%
Feb-07-19 09:00AM  Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm GlobeNewswire -6.42%
Jan-17-19 09:00AM  Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor GlobeNewswire
Dec-21-18 08:00AM  Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval GlobeNewswire +11.99%
Dec-20-18 03:37PM  Dawson James Securities Announces Closing of $2.0 Million Offering for Nemaura Medical, Inc. GlobeNewswire
Dec-19-18 08:00AM  Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments GlobeNewswire
Dec-18-18 02:01PM  Why Micro Cap Nemaura Medical Crashed 39.5% Today Motley Fool -39.22%
09:00AM  Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial GlobeNewswire
08:40AM  Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering GlobeNewswire
Dec-17-18 05:15PM  Nemaura Medical Announces Proposed Public Offering GlobeNewswire
Dec-12-18 08:00AM  Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin GlobeNewswire -12.26%
Dec-04-18 08:00AM  Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission GlobeNewswire
Nov-20-18 08:00AM  Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar GlobeNewswire
Nov-14-18 09:00AM  Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum GlobeNewswire -5.04%
Nov-12-18 09:00AM  Nemaura Medical to Present at the Stifel 2018 Healthcare Conference GlobeNewswire
Nov-08-18 09:00AM  Nemaura Medical Inc. Reports Second Quarter 2018 Financial Results GlobeNewswire +6.38%
Nov-07-18 09:00AM  Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT® GlobeNewswire
Oct-22-18 08:00AM  Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments GlobeNewswire +6.10%
Sep-25-18 08:00AM  Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor GlobeNewswire
Sep-18-18 08:00AM  Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar GlobeNewswire +5.83%
Sep-13-18 09:19AM  Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday Motley Fool +19.93%
Sep-12-18 08:00AM  Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial GlobeNewswire +32.69%
Aug-09-18 08:00AM  Nemaura Medical Inc. Reports First Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:00AM  Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study GlobeNewswire +6.94%
Jul-17-18 08:00AM  Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch Business Wire +13.53%
Jun-13-18 09:30AM  Nemaura Medical Inc. Reports Full Year Financial Results Business Wire +8.98%
May-30-18 09:30AM  Nemaura Medical Signs Joint Collaboration Agreement for European Commercialization Business Wire
May-15-18 09:30AM  Nemaura Medical to Present at the UBS Global Healthcare Conference Business Wire
Apr-09-18 09:30AM  Nemaura Medical Appoints Bashir Timol Chief Business Officer Business Wire +23.37%
Mar-28-18 11:05AM  Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel Business Wire
Mar-06-18 09:00AM  Nemaura Medical to Ring the Nasdaq Closing Bell Business Wire
Mar-05-18 10:50AM  CORRECTING and REPLACING -- Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
10:00AM  Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-01-18 04:18PM  Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch Business Wire
Feb-09-18 01:17PM  Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results Business Wire
Jan-31-18 01:20PM  Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program Business Wire +7.24%
Jan-23-18 09:00AM  Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018 Business Wire +6.38%
Dec-21-17 10:00AM  Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results Business Wire
Dec-06-17 09:00AM  Nemaura Announces Successful SugarBEAT® Interim Precision Study Results Business Wire
Nov-02-17 09:47AM  Nemaura Medical Inc. Reports Second Quarter 2017 Financial Results Business Wire
Sep-26-17 09:00AM  WallStreet Research Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc. Business Wire
Sep-21-17 09:00AM  Nemaura Announces Successful Interim Results for SugarBEAT® European Clinical Trials Business Wire
Aug-29-17 11:24AM  Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management Business Wire
Aug-15-17 12:47PM  Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand Business Wire
Aug-09-17 09:00AM  Nemaura Medical Inc. Reports First Quarter 2017 Financial Results Business Wire
Aug-03-17 09:00AM  Nemaura Appoints Thomas Moore to Board of Directors as Independent Director Business Wire
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. The company was founded in 2009 and is headquartered in Loughborough, the United Kingdom.